Biologic with Unique Mechanism of Action Trialed in Advanced Solid Tumors
Just five years ago, a team of researchers reported in the journal Cell that neutrophil elastase, an enzyme found in white blood cells, can kill cancer cells without collateral damage to healthy cells and that it can impede the formation of new tumors. The discovery has since been translated into a new intratumorally administered therapeutic elastase called N17350, now being evaluated in a phase 1/2 clinical trial for advanced solid tumors in adults.

Roswell Park Comprehensive Cancer Center is the only U.S. site outside of California and Texas to offer the trial. Benjamin Switzer, DO, MHSA, MS, Assistant Professor of Oncology at Roswell Park, is principal site investigator of NCT07339176, sponsored by Onchilles Pharma Inc.
Preclinical studies have demonstrated that this first-in-class biologic, which targets the neutrophil elastase ELANE pathway, can be effective in diverse types of solid tumors regardless of their genetic makeup, as well as in chemotherapy- and checkpoint inhibitor-resistant tumors, and that its potency remains undiminished with repeated dosing. Those studies have also shown evidence that it can trigger the abscopal effect, shrinking distant untreated tumors.
“We are thrilled to offer this trial to patients diagnosed with all primary solid tumor subtypes. The exciting preclinical activity was observed in dozens of tumor subtypes, including the presence of chemotherapy and immunotherapy resistance,” notes Dr. Switzer. “The dual activity of this therapy, through selective tumor cell death with simultaneous immune priming and activation, harnesses a mechanism that cannot be achieved through traditional chemotherapies or immunotherapies.”
The trial is open to patients with advanced solid tumors that are metastatic or inoperable, and for whom standard treatment options are unavailable, inappropriate or no longer effective.
The open-label study comprises two phases, dose-finding and dose expansion. Participants will receive intratumoral injections every other week for eight or 12 weeks. Phase 1 will evaluate the safety and optimal dosage for patients with any advanced solid tumor subtype exhibiting superficial and/or visceral sites of disease. Phase 2 will evaluate efficacy of the recommended dose from phase 1 in patients with triple-negative breast cancer, cutaneous squamous cell carcinoma, melanoma, non-small cell lung cancer and squamous cell carcinoma of the head and neck.
